✨ Medicines Notices
3022
NEW ZEALAND GAZETTE
No. 101
Health
Medicines Act 1981
Corrigendum
In the notice published in the New Zealand Gazette, 16 December 1993, No. 181, page 3752, notice No. 10671, for the strength “200 mg/ml” in the seventeenth line, replace the strength “200 mg/5 ml”.
Dated this 26th day of September 1994.
C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.
g07194
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Maprotiline hydrochloride 25 mg, 75 mg | Tablets | Merckle GmbH, Blaubeuren, Germany | Mapylin |
| Levodopa 100 mg, carbidopa 25 mg | Tablets | Alphapharm Pty Limited, Carole Park, Brisbane, Queensland, Australia | Sindopa |
| Cefpirome 250 mg, 500 mg, 1 g, 2 g (as the sulphate) | Powder for reconstitution for iv injection | Hoechst AG, Frankfurt am Main, Germany and Roussel Laboratories Limited, Swindon, Wiltshire, England | Cefrom |
Dated this 26th day of September 1994.
C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.
g07192
Consent to the Distribution of Changed Medicines
Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Ranitidine 150 mg/10 ml (as the hydrochloride) | Syrup | Glaxo Operations UK Limited, Barnard Castle, County Durham, England; Glaxo Operations UK Limited, Speke, Liverpool, England and Glaxo Operations UK Limited, Ware, Hertfordshire, England | Zantac |
| Ranitidine 150 mg, 300 mg (as the hydrochloride) | Tablets | Glaxo Operations UK Limited, Barnard Castle, County Durham, England; Glaxo Operations UK Limited, Ware, Hertfordshire, England; Glaxo Australia Pty Limited, Boronia, Victoria, Australia and Glaxo Pharmaceuticals Limited, Palmerston North | Zantac |
| Ranitidine 150 mg, 300 mg (as the hydrochloride) | Effervescent tablets | Glaxo Operations UK Limited, Ware, Hertfordshire, England and Laboratoires Glaxo SA, Zone Industrielle No 2, Evreux, France | Zantac |
| Ranitidine 150 mg, 300 mg (as the hydrochloride) | Effervescent granules | Glaxo Operations UK Limited, Ware, Hertfordshire, England and Laboratoires Glaxo SA, Zone Industrielle No 2, Evreux, France | Zantac |
Dated this 26th day of September 1994.
C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.
g07193
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1994, No 101
NZLII —
NZ Gazette 1994, No 101
✨ LLM interpretation of page content
🏥 Corrigendum to Medicines Notice
🏥 Health & Social Welfare26 September 1994
Corrigendum, Medicines Act 1981, Strength Correction
- C. Lovelace, Director-General of Health
🏥 Consent to Distribution of New Medicines
🏥 Health & Social Welfare26 September 1994
Medicines Act 1981, New Medicines, Distribution Consent
- C. Lovelace, Director-General of Health
🏥 Consent to Distribution of Changed Medicines
🏥 Health & Social Welfare26 September 1994
Medicines Act 1981, Changed Medicines, Distribution Consent
- C. Lovelace, Director-General of Health